Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
Watch CBS News
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.
The vaccine uses MRNA technology, which health secretary Robert F. Kennedy Jr. has called "unsafe and ineffective."
The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA technology, the company said.
This is because fewer people are getting COVID-19 vaccinations.
The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.
Federal health officials say thousands of updated booster shots are already being shipped around the country.
A Kaiser poll taken earlier this spring found fewer than one in five parents would get their children under 5 vaccinated right away.
The FDA's panel of vaccine advisers voted unanimously that the benefits of Pfizer's and Moderna's shots outweigh the risks in young children.
The FDA has pledged to "move with all expediency" to review the company's data on a lower-dose kids' vaccine.
"My hope would be that it would allow them not to have to quarantine if there was an exposure."
Moderna says its lower-dose COVID-19 vaccine works for babies and young children, some progress has been reported in the Proviso District 209 teachers’ strike, Sen. Dick Durbin took a more vocal role Wednesday during Supreme Court confirmation hearings for Judge Ketanji Brown Jackson, and loved ones said goodbye to Chicago legend Pervis Spann “The Blues Man.”
